Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28229700 | 0.91 | LMNA (0.49) | TSHRKMT2AMEN1GAAHTT | |
| SCHEMBL28704692 | 0.91 | HTT (0.46) | TSHRKMT2AMEN1GAAHTT | |
| SCHEMBL4625144 | 0.85 | KMT2A (0.61) | TSHRKMT2AMEN1GAAMAPT | |
| SCHEMBL10717862 | 0.84 | GAA (0.43) | TSHRKMT2AMEN1GAAMAPT | |
| SCHEMBL5694381 | 0.82 | ALDH1A1 (0.44) | TSHRKMT2AMEN1SCN1ASCN2A | |
| SCHEMBL6544700 | 0.82 | GAA (0.54) | TSHRKMT2AMEN1GAAHTT | |
| SCHEMBL6544633 | 0.80 | KMT2A (0.49) | TSHRKMT2AMEN1GAAMAPT | |
| SCHEMBL27403915 | 0.77 | TSHR (0.49) | TSHRKMT2AMEN1GAAMAPT | |
| Benzene SCHEMBL4123604 | 0.76 | KMT2A (0.38) | TSHRKMT2AMEN1GAASCN1A | |
| SCHEMBL7027544 | 0.76 | ELANE (0.41) | KMT2AMEN1HTTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122270-A1 | In-situ polymerization of monoethylenically unsaturated monomers with secondary amines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1428838-A1 | In situ-polymerization of monoethylenically unsaturated monomers with secondary amines | Bayer MaterialScience AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1428839-A1 | In-situ polymerization of monoethylenically unsaturated monomers with secondary amines | Bayer MaterialScience AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-6686424-B2 | USE IN RADICAL POLYMERIZATION; REACTING AN OXIDIZING AGENT WITH A STERICALLY HINDERED SECONDARY AMINE TO PRODUCE A NITROXY RADICAL; ADDING TO THE NITROXY RADICAL ONE OR MORE VINYL MONOMER | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-03 | — | — | US | disclosed |
| EP-1375457-A1 | One-pot process for the preparation of functionalized alkoxyamines | Bayer Aktiengesellschaft (DE) | 2004-01-02 | — | — | EP | disclosed |
| EP-1375476-A1 | A new process for the synthesis of alkoxyamines active in controlled radical polymerization | Bayer Aktiengesellschaft (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030236368-A1 | PREPARATION OF FUNCTIONALIZED ALKOXYAMINE INITIATOR AND ITS USE | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-25 | — | — | US | disclosed |
| US-6121393-A | USING A CATALYST OF A SOLID TITANIUM CATALYST COMPONENT CONTAINING MAGNESIUM, TITANIUM AND HALOGEN ATOMS, AN ORGANO-ALUMINUM COMPOUND, AND A BRANCHED CHAIN ALKYL CHLORIDE OR TITANIUM TETRACHLORIDE; STEREOSPECIFIC; POLYPROPYLENE | MITSUI CHEMICALS (JP) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236368-A1 | PREPARATION OF FUNCTIONALIZED ALKOXYAMINE INITIATOR AND ITS USE | NOS1, NOS2, CBR1 | TSHR 3966/4885KMT2A 1259/4885MEN1 2727/4885 |
| US-20040122270-A1 | In-situ polymerization of monoethylenically unsaturated monomers with secondary amines | ALOX5, PARG, FASN | TSHR 4635/4885KMT2A 1375/4885MEN1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.